Does Elmiron cause Pigmentary Maculopathy?
For patients across Washington who took Elmiron (pentosan polysulfate sodium) for interstitial cystitis, the discovery of permanent retinal damage—Elmiron Pigmentary Maculopathy—has reshaped both medical practice and legal accountability. As of 2026, our firm continues to represent Washington residents who developed vision loss after years of Elmiron use, navigating a complex landscape of consolidated multidistrict litigation (MDL) and evolving FDA safety labeling. We are here to help you understand your rights and the current state of evidence linking this drug to macular degeneration.
Elmiron Maculopathy in Washington: The 2020-2026 Legal Timeline
The first major studies connecting Elmiron to pigmentary maculopathy emerged in 2018 and 2019, but it wasn't until 2020 that the FDA required a new warning label. Washington patients, many of whom had taken Elmiron for over a decade, began filing injury claims in state and federal courts. By 2022, the federal cases were consolidated into MDL No. 2973 in the District of New Jersey. Key developments include:
| Year | Event | Impact on Washington Cases |
|---|---|---|
| 2018 | Dr. Nieraj Jain's study published in Ophthalmology linking Elmiron to retinal toxicity | First clinical evidence used in Washington complaints |
| 2020 | FDA mandates label change; first Washington state court filings | King County Superior Court sees initial Elmiron lawsuits |
| 2022 | MDL No. 2973 established; bellwether trials begin | Washington plaintiffs join federal MDL; discovery on dosage thresholds |
| 2024 | Second bellwether trial results; Janssen (Johnson & Johnson) settles select cases | Washington attorneys negotiate individual settlements |
| 2026 | Ongoing state court litigation; new research on cumulative dose risks | Washington patients still filing claims; statute of limitations varies by county |
Retinal Damage Thresholds: What Washington Patients Need to Know in 2026
Our Washington clients often ask: "How much Elmiron causes permanent vision loss?" Recent 2025-2026 studies from the University of Washington and the Casey Eye Institute clarify that cumulative dose is the critical factor. Patients who took more than 1,500 grams of pentosan polysulfate sodium over their lifetime face the highest risk of pigmentary maculopathy. This typically corresponds to 5-7 years of daily use at standard doses (100 mg three times daily).
- Early symptoms: Difficulty reading, prolonged dark adaptation (slow adjustment to dim light), and paracentral scotomas (blind spots near central vision).
- Diagnostic tools: Optical coherence tomography (OCT) and fundus autofluorescence (FAF) are now standard in Washington ophthalmology practices for detecting Elmiron-related retinal changes.
- Irreversible damage: Unlike some drug-induced retinopathies, Elmiron maculopathy does not improve after stopping the medication—making early legal intervention critical.
"The link between Elmiron and pigmentary maculopathy is now beyond scientific dispute. Our Washington clients have undergone years of unnecessary vision loss because the manufacturer failed to adequately warn patients and physicians until 2020. We continue to hold Janssen Pharmaceuticals accountable through both MDL proceedings and individual state court actions." — Our legal team, referencing the original 2018 Jain study and the 2020 FDA label change. See the archived case materials at our earlier Washington Elmiron page and the current MDL docket at antiquestopic.com.
Washington State Court Strategy: Statute of Limitations and Medical Record Preservation
In 2026, Washington law provides a three-year statute of limitations for personal injury claims from the date the injury was discovered—or should have been discovered. For Elmiron patients, this "discovery rule" often starts when an ophthalmologist first diagnoses pigmentary maculopathy and links it to the medication. However, many Washington patients were diagnosed as early as 2020 but delayed filing, believing the damage was age-related macular degeneration. Our firm reviews each client's medical timeline to ensure claims are timely.
We also emphasize the importance of preserving complete pharmacy records, prescription histories, and all retinal imaging. Washington courts have required expert testimony from both retinal specialists and pharmacologists to establish causation. As of 2026, the standard of proof in Washington Elmiron cases requires showing:
- A diagnosis of pigmentary maculopathy confirmed by OCT or FAF
- A documented history of Elmiron use for at least six months
- Exclusion of other causes (e.g., age-related macular degeneration, pattern dystrophy)
- Cumulative dose exceeding 500 grams (though higher doses strengthen the case)
Our Washington Elmiron injury practice remains active, offering free case evaluations for patients in Seattle, Spokane, Tacoma, and throughout the state. We continue to monitor the MDL for any global settlement announcements while preparing individual cases for trial if necessary.